Resources and governance insight for clinicians and healthcare providers.
Grow Group has announced the completion of a recapitalisation, has appointed Co-CEOs, and now expects to generate healthy EBITDA in 2027.
By Ben Stevens, with additional reporting by Nicole Farah, Managing Director of Americana Communications.
Australia’s ongoing efforts to restrict its medical cannabis market, now the largest outside North America, are now taking aim at the special access scheme (SAS) framework on which the country’s hundreds of thousands of annual prescriptions are based.
As Aurora faces down an unsolicited takeover bid from one of the world’s largest cannabis companies, it has continued to expand its reach in what it sees as the markets of the near future.
The UK has another new Prime Minister, Andy Burnham, who has wasted no time in laying out his plans to fundamentally reform the country’s creaking healthcare infrastructure.
Cantourage Group SE has announced the launch of its first proprietary medical cannabis brand for the German market, in a meaningful pivot for the distributor.
The UK medical cannabis sector has spent seven years arguing for access.
Written for Business of Cannabis by Saxon Coop, Founder & CEO of Toke.
New data acquired by Business of Cannabis has, for the first time, shed light on the professional types behind England’s CBPM prescribing record, raising further questions about assertions that ‘10 doctors prescribe half of the UK’s medical cannabis’.
